TABLE 4.

Immunogenicities of Fluad and Agrippala in HIV-1-seronegative subjects

ParameterVirus and vaccine
A/H3/California/07/04A/H1/New Caledonia/20/99B/Shangai/361/02
FluadAgrippalFluadAgrippalFluadAgrippal
No. (%) of subjects who underwent seroconversion53 (66)49 (69)49 (61)42 (59)51 (64)45 (63)
No. (%) of subjects with seroprotection
    T049 (61)49 (69)55 (69)47 (66)63 (79)51 (72)
    T3077 (96)69 (97)75 (94)64 (90)77 (96)66 (93)
    T9070 (95)65 (98)69 (93)60 (91)70 (95)62 (94)
GMT
    T076.999.6109.482.8137.2100.6
    T30787.9740.91,030.7630.7929.2685.2
    T90429.7554.1712.3392.7650.3517
GMT ratio
    T30/T010.247.439.427.616.776.81
    T90/T05.595.566.514.744.745.14
Adjusted mean titer at T30 according to Beyer method5.59 ± 1.935.28 ± 1.776.08 ± 2.235.07 ± 2.066.25 ± 1.825.4 ± 2.64
Corresponding mean antibody titer at T30240.4194.28337.4167.52*380.36212.22**
  • a Samples were tested for 80 and 71 subjects, respectively, at T30 and for 74 and 66 subjects, respectively at T90. *, P = 0.005; **, P = 0.023.